Risk of immunodeficiency virus infection may increase with vaccine-induced immune response

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10533-10539

  Tenbusch, Matthias ^a   Ignatius, Ralf ^b   Temchura, Vladimir ^a   Nabi, Ghulam ^a   Tippler, Bettina ^a   Stewart Jones, Guillaume ^c   Salazar, Andres M ^d   Sauermann, Ulrike ^e   Stahl Hennig, Christiane ^e   Überla, Klaus ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Oncovir Inc   (United States)

^e GERMAN PRIMATE CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; MOCK; SCDEC P27; SCISO P27; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA IMMUNIZATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS INACTIVATION; VIRUS NEUTRALIZATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; HEK293 CELLS; HUMANS; IMMUNE SYSTEM; INTERFERON-GAMMA; MACACA; MACACA MULATTA; MALE; MICE; PEPTIDES; RISK; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; MACACA; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84868157389     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00796-12     Document Type: Article

References (26)

1. Benlahrech A, et al. 2009. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl. Acad. Sci. U. S. A. 106:19940-19945.
2. Buchbinder SP, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
3. Douek DC, et al. 2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417:95-98.
4. Flynn BJ, et al. 2011. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 108:7131-7136.
5. Flynn NM, et al. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191: 654-665.
6. Keele BF, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
7. Masek-Hammerman K, et al. 2010. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J. Virol. 84:9810-9816.
8. McElrath MJ, et al. 2008. HIV-1 vaccine-induced immunity in the testof-concept STEP study: a case-cohort analysis. Lancet 372:1894-1905.
9. Neildez O, et al. 1998. Variation in virological parameters and antibody responses in macaques after atraumatic vaginal exposure to a pathogenic primary isolate of SIVmac251. Res. Virol. 149:53-68.
10. O'Brien KL, et al. 2009. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat. Med. 15:873-875.
11. Ochieng W, et al. 2009. Susceptibility to simian immunodeficiency virus ex vivo predicts outcome of a prime-boost vaccine after SIVmac239 challenge. J. Acquir. Immune Defic. Syndr. 52:162-169.
12. + T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J. Clin. Invest. 121: 4433-4445.
13. Pitisuttithum P, et al. 2006. Randomized, double-blind, placebocontrolled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671.
14. Qureshi H, et al. 2012. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb STEP trial of a similar HIV-1 vaccine. J. Virol. 86:2239-2250.
15. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
16. Sauermann U, et al. 2008. Mhc class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques. Genes Immun. 9:69-80.
17. Schulte R, et al. 2009. Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques. Virology 383:300-309.
18. Schultheiss T, Schulte R, Sauermann U, Ibing W, Stahl-Hennig C. 2011. Strong mucosal immune responses in SIV infected macaques contribute to viral control and preserved CD4+ T-cell levels in blood and mucosal tissues. Retrovirology 8:24.
19. Sekaly R-P. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205:7-12.
20. Soghoian DZ, et al. 2012. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci. Transl. Med 4:123ra25. doi:10.1126/scitranslmed.3003165.
21. Stahl-Hennig C, et al. 2009. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 5:e1000373. doi:10.1371/journal.ppat.1000373.
22. Staprans SI, et al. 2004. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc. Natl. Acad. Sci. U. S. A. 101:13026-13031.
23. Tenbusch M, et al. 2012. Immunogenicity of DNA vaccines encoding dendritic cell targeted simian immunodeficiency virus antigen in rhesus macaques. PLoS One 7:e39038. doi:10.1371/journal.pone.0039038.
24. Überla K. 2008. HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection? PLoS Pathog. 4:e1000114. doi:10.1371/journal.ppat.1000114.
25. + T cells are rapidly eliminated in early SIV infection in vivo. J. Virol. 74:57-64.
26. Wagner R, et al. 2000. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type. Hum. Gene Ther. 11:2403-2413.